A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease (VitaliThy)

November 2, 2026 updated by: argenx

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.

The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.

The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.

More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Study Overview

Study Type

Interventional

Enrollment (Estimated)

230

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Tbilisi, Georgia, 0114
      • Tbilisi, Georgia, 0102
      • Tbilisi, Georgia, 0119
      • Tbilisi, Georgia, 0112
      • Tbilisi, Georgia, 0159
        • Recruiting
        • In Vitro Fertilization Center LLC
        • Contact:
    • Tyne and Wear
      • Gateshead, Tyne and Wear, United Kingdom, NE9 6SX
        • Recruiting
        • Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)
        • Contact:
    • California
      • Carlsbad, California, United States, 92012
      • Orange, California, United States, 92868
        • Recruiting
        • Diabetes Associates Medical Group
        • Contact:
      • Pasadena, California, United States, 91101
      • Pasadena, California, United States, 91105
      • San Jose, California, United States, 95128
    • Florida
      • Fleming Island, Florida, United States, 32003
        • Recruiting
        • Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location
        • Contact:
      • Fort Lauderdale, Florida, United States, 33312
      • Jacksonville, Florida, United States, 32256
        • Recruiting
        • University of Florida Jacksonville College of Medicine
        • Contact:
      • Kissimmee, Florida, United States, 34744
        • Recruiting
        • Ilumina Medical Research LLC
        • Contact:
      • Miami, Florida, United States, 33144
    • Kansas
      • Lenexa, Kansas, United States, 66219
        • Recruiting
        • Johnson County Clin-Trials, Inc.
        • Contact:
      • Wichita, Kansas, United States, 67226
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Recruiting
        • University of Michigan
        • Contact:
      • Dearborn, Michigan, United States, 48126
        • Recruiting
        • Metro Detroit Endocrinology Center
        • Contact:
      • Farmington Hills, Michigan, United States, 48334
    • Missouri
      • Kansas City, Missouri, United States, 64108
    • New York
      • Albany, New York, United States, 12203
        • Recruiting
        • Albany Medical College Community Endocrinology
        • Contact:
      • New York, New York, United States, 10016
        • Recruiting
        • Endocrine Associates of West Village PC
        • Contact:
    • North Carolina
      • Asheville, North Carolina, United States, 28803
      • Raleigh, North Carolina, United States, 27612
    • Texas
      • Dallas, Texas, United States, 75231
        • Recruiting
        • Research Institute of Dallas
        • Contact:
      • El Paso, Texas, United States, 79935
        • Recruiting
        • Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine
        • Contact:
      • Houston, Texas, United States, 77040
        • Recruiting
        • Juno Research
        • Contact:
      • Houston, Texas, United States, 77089
        • Recruiting
        • Clinic of Endocrinology
        • Contact:
      • Irving, Texas, United States, 75039
      • McAllen, Texas, United States, 78503
        • Recruiting
        • Biopharma Informatic, LLC
        • Contact:
      • McKinney, Texas, United States, 75069
      • Mesquite, Texas, United States, 75149
        • Recruiting
        • Southern Endocrinology Associates PA
        • Contact:
      • Shavano Park, Texas, United States, 78231

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF.
  • Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening.
  • Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening.
  • Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening.

Exclusion Criteria:

  • History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter).
  • History of RAI (radioactive iodine) therapy or received a total thyroidectomy.
  • T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening.
  • Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications.
  • Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part A - efgartigimod PH20 SC PFS

Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

Placebo Comparator: Part A - placebo PH20 SC PFS

Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

Experimental: Part B - efgartigimod PH20 SC PFS

Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

Experimental: Part B - placebo PH20 SC PFS

Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

Experimental: Part C - efgartigimod PH20 SC PFS

Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period

Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Time Frame: Up to 24 weeks (part A)

Free triiodothyronine: [fT3]; free thyroxine: [fT4]; ATDs: antithyroid drugs

Up to 24 weeks (part A)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to becoming euthyroid
Time Frame: Up to 24 weeks (part A) + up to 135 weeks
Up to 24 weeks (part A) + up to 135 weeks
Efgartigimod serum concentrations over time
Time Frame: Up to 24 weeks (part A) + 72 weeks (part C)
Up to 24 weeks (part A) + 72 weeks (part C)
Time to becoming euthyroid off ATDs in part A
Time Frame: Up to 24 weeks (part A)

ATDs: antithyroid drugs

Up to 24 weeks (part A)
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
Time Frame: Up to 24 weeks (part A)

MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

Up to 24 weeks (part A)
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
Time Frame: Up to 24 weeks (part A)

ULN : upper limit of normal; ATDs: antithyroid drugs.

Up to 24 weeks (part A)
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
Time Frame: Up to 24 weeks (part A)

TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs.

Up to 24 weeks (part A)
Time to becoming euthyroid off ATDs and TRAb seronegative
Time Frame: Up to 24 weeks (part A) + up to 135 weeks

ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies.

Up to 24 weeks (part A) + up to 135 weeks
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
Time Frame: Up to 24 weeks (Part A)

ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

Up to 24 weeks (Part A)
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
Time Frame: Up to 24 weeks (part A)

TSH: thyroid-stimulating hormone; LLN: lower limit of normal.

Up to 24 weeks (part A)
Percentage of participants who remain euthyroid without ATDs
Time Frame: Up to 74 weeks (part B)

ATDs: antithyroid drug

Up to 74 weeks (part B)
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
Time Frame: Up to 74 weeks (part B) + up to 135 weeks

ATDs: antithyroid drug

Up to 74 weeks (part B) + up to 135 weeks
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
Time Frame: Up to 72 weeks (part C)

ATDs: antithyroid drug

Up to 72 weeks (part C)
Incidence of AEs and SAEs
Time Frame: Up to 135 weeks

AEs: adverse events ; SAEs: serious adverse events.

Up to 135 weeks
Change in ThyPRO-39 over time
Time Frame: Up to 135 weeks

The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status.

Up to 135 weeks
Change in PROMIS-PF10a over time
Time Frame: Up to 135 weeks

The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.

Up to 135 weeks
Percentage change from baseline in total IgG levels in serum over time
Time Frame: Up to 98 weeks

IgG: immunoglobulin G

Up to 98 weeks
Percentage change from baseline in TRAb serum levels over time
Time Frame: Up to 135 weeks

TRAb: anti-TSHR autoantibodies.

Up to 135 weeks
Incidence of ADA against efgartigimod in serum
Time Frame: Up to 24 weeks (part A) + up to 135 weeks

ADA: antidrug antibody(ies)

Up to 24 weeks (part A) + up to 135 weeks
Incidence of antibodies against rHuPH20 in plasma
Time Frame: Up to 24 weeks (part A) + Up to 135 weeks

rHuPH20: recombinant human hyaluronidase PH20

Up to 24 weeks (part A) + Up to 135 weeks
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
Time Frame: Up to 24 weeks (part A) + up to 135 weeks

NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20.

Up to 24 weeks (part A) + up to 135 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 10, 2026

Primary Completion (Estimated)

June 1, 2028

Study Completion (Estimated)

May 1, 2030

Study Registration Dates

First Submitted

April 30, 2026

First Submitted That Met QC Criteria

April 30, 2026

First Posted (Actual)

May 6, 2026

Study Record Updates

Last Update Posted (Actual)

November 3, 2026

Last Update Submitted That Met QC Criteria

November 2, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ARGX-113-25-GRD-3002
  • 2025-524223-42-00 (Ctis)
  • 2025 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe